Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer
| Autor: | Martin, Götte, Christian, Kersting, Maria, Ruggiero, Joke, Tio, Augustinus H, Tulusan, Ludwig, Kiesel, Pia, Wülfing |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Membrane Glycoproteins Syndecans Carcinoma Ductal Breast Granulocyte-Macrophage Colony-Stimulating Factor Breast Neoplasms Middle Aged Immunohistochemistry Neoadjuvant Therapy Chemotherapy Adjuvant Predictive Value of Tests Antineoplastic Combined Chemotherapy Protocols Humans Female Proteoglycans Syndecan-1 Cyclophosphamide Aged Epirubicin |
| Zdroj: | Anticancer research. 26(1B) |
| ISSN: | 0250-7005 |
| Popis: | The overexpression of syndecan-1 in breast carcinomas correlates with poorer prognosis and an aggressive phenotype. The effect of syndecan-1 expression on tumor response to neoadjuvant chemotherapy was determined in locally advanced breast cancer.Semi-quantitative syndecan-1 immunohistochemistry was performed in pre-chemotherapy breast cancer biopsies of 37 patients undergoing high-dose neoadjuvant treatment with cyclophosphamide and epirubicin.43.2% of breast carcinomas stained positive for syndecan-1. Syndecan-1 expression was more frequent in ductal invasive carcinomas than in other histological types (p=0.062). The pathological response to chemotherapy was decreased in syndecan-1-positive patients: 37.5% of syndecan-1-positive vs. 19% of syndecan-1-negative patients attained pathologically "no change". No syndecan-1-positive patient showed complete remission. Also, a correlation between syndecan-1 immunostaining intensity and response to chemotherapy was observed. Of the responding tumors, none showed strong syndecan-1 expression (Score 3+), whereas 20% of the non-responding tumors were strongly syndecan-1-positive.Syndecan-1-expressing breast carcinomas show a trend towards a decreased response to chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|